USD10
CGEN Shares
About CompugenCompugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
USD10
CGEN Shares
About CompugenCompugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 23 at 1:30 PM GMT+0
MARKET CAP
$197.70M
OPEN PRICE
Not enough data
LOW (1Y)
$1.13
HIGH (1Y)
$2.38
LOW (24H)
$2.02
HIGH (24H)
$2.12
VOLUME (24H)
$3.16K
98.87%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $2.02 | |
1 Week | $2.25 | |
1 Month | $1.67 | |
1 Year | $1.62 |